



Verastem Oncology was founded on the principle that our work should focus on how we can uniquely contribute to advancing the science to bring new medicines to cancer patients. In partnership with the healthcare community, we have made tremendous strides in bringing forward therapies for patients who did not have adequate options. In announcing the definitive agreement to sell COPIKTRA® (duvelisib) and reaffirming our future focused on developing our RAF/MEK and FAK program, we believe we have taken the steps required to best deliver on our mission.

As we look toward our Company's new chapter, one thing is clear. Despite massive advances across oncology treatment, there is still much work to be done. This is the reality that fuels us. Thirty percent of all human cancers are driven by mutations in the RAS family of genes and conventional approaches have not delivered optimal results. Our research into the combination of RAF/MEK and FAK has already shown promising results, and we are excited at the prospect of bringing scientific advancement to an area that requires new approaches – and potentially developing and advancing the backbone to treat RAS mediated tumors.

Thank you to the healthcare professionals, partners, colleagues and investors who have helped us deliver for patients, setting the foundation for COPIKTRA to continue to help more patients around the world.

We are excited about the future, contributing to our understanding of challenging areas in oncology treatment and advancing new therapies for patients.

Sincerely,

Brian Stuglik
CEO
Verastem Oncology